Table 1.
Demographics and clinical variables of our PD cohort
| Variables | Mean |
|---|---|
| Male, N (%) | 21 (39.6%) |
| Age, years (SD) | 61.6 (10.9) |
| Disease duration, years (SD) | 6.6 (6.8) |
| UPDRS, (SD) | |
| Part I | 13.9 (6.0) |
| Part II | 14.3 (8.5) |
| Part III | 27.7 (14.9) |
| Part IV | 2.4 (3.4) |
| LED mg, (SD) | 643 (432.5) |
| Hoehn–Yahr stage, N (%) | |
| Stage 1 | 6 (11.3%) |
| Stage 2 | 34 (64.2%) |
| Stage 3 | 10 (18.9%) |
| Stage 4 | 3 (5.7%) |
| Dopaminergic medication, N (%) | 52 (98.1%) |
| Dopamine agonist | 44 (83.0%) |
| Levodopa therapy | 40 (75.5%) |
| MAOBIs | 9 (17.0%) |
| Nondopaminergic medication, N (%) | |
| Antidepressants | 17 (32.1%) |
| Antipsychotic | 1 (1.9%) |
| Sleep inductors | 8 (15.1%) |
| ICDs, N (%) | 10 (18.9%) |
| Binge eating | 4 (7.5%) |
| Sexual behaviors | 4 (7.5%) |
| Shopping | 4 (7.5%) |
| Gambling | 2 (3.8%) |
| Hobbyism–punding | 8 (15.1%) |
| Combination of ICDs | 5 (9.4%) |
| Sleep, N (%) | 43 (81.1%) |
| OSA | 30 (56.6%) |
| RBD | 26 (49.1%) |
| PLMD | 14 (26.4%) |
| Combination of sleep disorders | 22 (41.5%) |
PD, Parkinson's disease; UPDRS, Unified Parkinson's Disease Rating Scale; LED, levodopa equivalent dosage; MAOBIs, monoamine oxidase type B inhibitors; ICDs, impulse control disorders; OSA, obstructive sleep apnea; RBD, REM behavioral sleep disorder; PLMDs, periodic limb movement disorders.